Tirzepatide is available in weekly subcutaneous doses of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg (Table 1)
Asia-Pacific (including Japan) - Strongest growth region supported by rising diabetic population, expanding healthcare access, increasing awareness, and large-scale pharmaceutical manufacturing in China, India, and Southeast Asia, along with Japan's advanced diabetes care ecosystem
They can reduce oxidative stress, show anti-inflammatory and anti-tumorigenic properties, alter glycemic control and lipid metabolism, and alter the release of inflammatory cytokines and chemokines (20, 21)
GHK-Cu has well-documented topical bioavailability and is the basis of many cosmetic serums